Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study).

CONCLUSIONS: For this nAMD population, no visual or anatomical benefits were observed when treating with DXI in adjunct to ranibizumab relative to ranibizumab monotherapy. DXI-related adverse events were consistent with those previously documented for dexamethasone. PMID: 27521672 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/27521672?dopt=Abstract

Source: Canadian Journal of Ophthalmology - July 31, 2016 Category: Opthalmology Authors: Chaudhary V, Barbosa J, Lam WC, Mak M, Mavrikakis E, Mohaghegh P SM Tags: Can J Ophthalmol Source Type: research